Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP098
MIFTS: 65

Hypereosinophilic Syndrome

Categories: Rare diseases, Immune diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hypereosinophilic Syndrome

About this section

MalaCards integrated aliases for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 12 76 53 37 55 44 15 73
Eosinophilia 12 76 29 55 44 73
Disseminated Eosinophilic Collagen Disease 73
Hypereosinophilic Syndrome, Idiopathic 53
Idiopathic Hypereosinophilic Syndrome 73
Ferric Dihydrolipoate Complex 44
Eosinophilic Leukocytosis 12
Eosinophilic Disorder 73
Hes 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:999
ICD10 33 D72.1
ICD9CM 35 288.3
KEGG 37 H01599
Sources

Summaries for Hypereosinophilic Syndrome

About this section
NIH Rare Diseases : 53 Hypereosinophilic syndrome (HES) refers to a rare group of conditions that are associated with persistent eosinophilia with evidence of organ involvement. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases. Management varies based on the severity of the condition and whether or not an underlying cause has been identified but generally includes imatinib or corticosteroids as an initial treatment.

MalaCards based summary : Hypereosinophilic Syndrome, also known as eosinophilia, is related to primary hypereosinophilic syndrome and hypereosinophilic syndrome, idiopathic, and has symptoms including pruritus, myalgia and abdominal pain. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5.0×108/l... more...

Sources

Related Diseases for Hypereosinophilic Syndrome

About this section

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 primary hypereosinophilic syndrome 34.1 FGFR1 FIP1L1 PDGFRA PDGFRB
2 hypereosinophilic syndrome, idiopathic 33.5 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
3 endomyocardial fibrosis 32.6 FIP1L1 IL4 PDGFRA
4 eosinophilic colitis 31.2 PRG2 RNASE3
5 wells syndrome 30.6 IL2RA IL5 RNASE3
6 churg-strauss syndrome 30.5 CCL17 IL5 RNASE3
7 loeffler endocarditis 30.5 FIP1L1 IL5 PDGFRA RNASE3
8 chronic eosinophilic leukemia 30.5 ABL1 FGFR1 FIP1L1 IFNA1 KIT PDGFRA
9 systemic mastocytosis 30.0 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
10 gastroenteritis 29.7 CCL11 IFNA1 IL4 IL5 RNASE3
11 bullous pemphigoid 29.6 CCL11 CCL17 IL5 RNASE3
12 mycosis fungoides 29.5 CCL17 IFNA1 IL2RA IL5
13 esophagitis, eosinophilic, 1 29.2 CCL11 IL13 IL5
14 esophagitis 29.1 CCL11 IL13 IL5
15 mast cell disease 29.0 IL13 IL5 KIT PDGFRA PDGFRB
16 pulmonary eosinophilia 29.0 CCL11 CCL17 EPX IL13 IL4 IL5
17 cutaneous t cell lymphoma 28.9 CCL17 IFNA1 IL2RA IL4
18 eosinophilic gastroenteritis 28.9 CCL11 CSF2 EPX IL3 IL5 RNASE3
19 myeloid leukemia 28.5 ABL1 CSF2 IL3 KIT
20 eosinophilic meningitis 28.4 CCL11 IL13 IL4 IL5
21 eosinophilic gastritis 27.9 CCL11 IL13 IL3 IL4 IL5
22 eosinophilic pneumonia 26.6 CCL11 CCL17 CSF2 IL13 IL3 IL5
23 dermatitis 25.8 CCL11 CCL17 IGES IGHE IL13 IL4
24 asthma 23.0 CCL11 CCL17 CSF2 EPX IGES IGHE
25 eosinophilia, familial 12.3
26 eosinophilia-myalgia syndrome 12.3
27 myeloproliferative disorder, chronic, with eosinophilia 12.3
28 lymphocytic hypereosinophilic syndrome 12.1
29 secondary hypereosinophilic syndrome 12.1
30 pdgfra-associated chronic eosinophilic leukemia 11.0 FIP1L1 PDGFRA
31 episodic angioedema with eosinophilia 10.9
32 reticular perineurioma 10.8 KIT PDGFRA
33 sm-ahnmd 10.8 FIP1L1 KIT PDGFRA
34 corneal dystrophy, subepithelial mucinous 10.7 FIP1L1 PDGFRA PDGFRB
35 pemphigoid gestationis 10.7 CCL11 IL5
36 desmoid tumor 10.7 KIT PDGFRA PDGFRB
37 heart sarcoma 10.7 KIT PDGFRA PDGFRB
38 cellular neurofibroma 10.7 ABL1 PDGFRB
39 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.7 FGFR1 PDGFRA PDGFRB
40 chronic eosinophilic pneumonia 10.6 CCL11 IL5 RNASE3
41 fibrosarcoma of bone 10.6 KIT PDGFRA PDGFRB
42 eosinophilic granuloma 10.6 EPX RNASE3
43 dermatofibrosarcoma protuberans 10.6 KIT PDGFRA PDGFRB
44 8p11 myeloproliferative syndrome 10.5 FGFR1 KIT PDGFRB
45 leiomyosarcoma 10.5 KIT PDGFRA PDGFRB
46 bronchitis 10.5 CCL11 IL5 RNASE3
47 atypical chronic myeloid leukemia 10.4 ABL1 FGFR1 PDGFRA
48 cough variant asthma 10.4 IL4 IL5 RNASE3
49 leukemia 10.3
50 milk allergy 10.3 IL4 IL5 RNASE3

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to Hypereosinophilic Syndrome
Sources

Symptoms & Phenotypes for Hypereosinophilic Syndrome

About this section

UMLS symptoms related to Hypereosinophilic Syndrome:


pruritus, myalgia, abdominal pain, angina pectoris, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, heartburn, icterus, nausea and vomiting, snoring, gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.68 PDGFRA
2 Decreased viability GR00221-A-1 9.68 KIT PDGFRA PDGFRB ABL1 FGFR1
3 Decreased viability GR00221-A-2 9.68 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.68 PDGFRA PDGFRB ABL1
5 Decreased viability GR00221-A-4 9.68 PDGFRA PDGFRB
6 Decreased viability GR00301-A 9.68 KIT
7 Decreased viability GR00342-S-1 9.68 PDGFRB ABL1
8 Decreased viability GR00342-S-2 9.68 ABL1
9 Decreased viability GR00342-S-3 9.68 ABL1
10 Decreased viability GR00402-S-2 9.68 PDGFRA PDGFRB ABL1 FGFR1 KIT
11 Decreased substrate adherent cell growth GR00193-A-1 9.43 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.43 KIT ABL1
13 Decreased substrate adherent cell growth GR00193-A-4 9.43 KIT ABL1 FGFR1

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 EPX FGFR1 PDGFRA IL13 PDGFRB IL2RA
2 digestive/alimentary MP:0005381 9.97 KIT FGFR1 PDGFRA IL13 IL2RA ABL1
3 craniofacial MP:0005382 9.91 KIT FGFR1 PDGFRA ABL1 IL4 CSF2
4 endocrine/exocrine gland MP:0005379 9.91 CSF2 KIT FGFR1 PDGFRA IL13 IL2RA
5 immune system MP:0005387 9.8 KIT EPX FGFR1 PDGFRA IL13 IL2RA
6 respiratory system MP:0005388 9.32 KIT PDGFRA IL13 IL2RA ABL1 IL4
Sources

Drugs & Therapeutics for Hypereosinophilic Syndrome

About this section

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4 Prednisolone acetate Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 2,Phase 3
6 Respiratory System Agents Phase 4,Phase 2,Phase 3
7 Methylprednisolone acetate Phase 4,Phase 3
8 Methylprednisolone Hemisuccinate Phase 4,Phase 3
9 Adrenergic Agents Phase 4,Phase 2
10 Adrenergic Agonists Phase 4,Phase 2
11 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
12 Adrenergic beta-Agonists Phase 4,Phase 2
13 Albuterol Phase 4,Phase 2
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
15 Neuroprotective Agents Phase 4,Phase 3
16 Neurotransmitter Agents Phase 4,Phase 2
17 Tocolytic Agents Phase 4,Phase 2
18 Hormone Antagonists Phase 4,Phase 2,Phase 3
19 Hormones Phase 4,Phase 2,Phase 3
20 Anti-Allergic Agents Phase 4,Phase 2
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
22 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
25 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
26 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3
27 Prednisolone hemisuccinate Phase 4,Phase 3
28 Prednisolone phosphate Phase 4,Phase 3
29 Antiemetics Phase 4,Phase 3,Phase 2
30 Protective Agents Phase 4,Phase 3,Phase 2
31 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
32 Autonomic Agents Phase 4,Phase 3,Phase 2
33 Bronchodilator Agents Phase 4,Phase 2
34 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
35
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
36
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
37
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
38
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
39
Daunorubicin Approved Phase 3 20830-81-3 30323
40
Thioguanine Approved Phase 3 154-42-7 2723601
41
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
42
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3 53-03-2 5865
43 Interleukin-2 Phase 3
44 Analgesics Phase 3,Phase 2,Phase 1
45 Alkylating Agents Phase 3,Phase 2,Not Applicable
46
asparaginase Phase 3
47 Analgesics, Non-Narcotic Phase 3
48 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
49 N-Methylaspartate Phase 3
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
4 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
9 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
10 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
11 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
12 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
13 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
14 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
15 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
16 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
17 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
18 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Not yet recruiting NCT03470311 Phase 3
19 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
20 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
21 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
22 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
23 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
24 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
25 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
26 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
27 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
28 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
29 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
30 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
31 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
32 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
33 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
34 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
35 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
36 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
37 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
38 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
39 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
40 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
41 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
42 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
43 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
44 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib Mesylate
45 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Recruiting NCT02071901 Phase 2 eltrombopag olamine
46 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
47 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Recruiting NCT03469934 Phase 2 ANB020;Placebo
48 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Recruiting NCT02560610 Phase 2 OC000459;Placebo
49 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab
50 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2 Dexpramipexole

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hypereosinophilic syndrome

Sources

Genetic Tests for Hypereosinophilic Syndrome

About this section

Genetic tests related to Hypereosinophilic Syndrome:

# Genetic test Affiliating Genes
1 Eosinophilia 29
Sources

Anatomical Context for Hypereosinophilic Syndrome

About this section

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

41
Myeloid, Bone, Heart, Skin, T Cells, Testes, Bone Marrow
Sources

Publications for Hypereosinophilic Syndrome

About this section

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 708)
# Title Authors Year
1
Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. ( 28986919 )
2018
2
Cardiac involvement in hypereosinophilic syndrome. ( 29922025 )
2018
3
Hypereosinophilic Syndrome Complicated by Eosinophilic Myocarditis With Dramatic Response to Steroid. ( 29581993 )
2018
4
Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. ( 29496465 )
2018
5
Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. ( 29751154 )
2018
6
Bilateral Conjunctival Granulomas in A Young Lady with Hypereosinophilic Syndrome - A Case Report. ( 29771605 )
2018
7
Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome. ( 29924226 )
2018
8
A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome. ( 29794385 )
2018
9
Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. ( 29780651 )
2018
10
FIP1L1-PDGFRA fusion-negative hypereosinophilic syndrome with uncommon cardiac involvement responding to imatinib treatment: A case report. ( 29977537 )
2018
11
Eosinophilic Fasciitis in Association With Hypereosinophilic Syndrome in an HIV-Infected Patient With Severe Multiorgan Involvement. ( 29661739 )
2018
12
Hypereosinophilic syndrome presenting acutely with neurologic signs. ( 29501486 )
2018
13
Hypereosinophilic syndrome preceding a diagnosis of B-cell lymphoma. ( 29714651 )
2018
14
Hypereosinophilic Syndrome in the Differential Diagnosis of Pulmonary Infiltrates with Eosinophilia. ( 29803709 )
2018
15
Lymphocytic variant of hypereosinophilic syndrome presenting with polymorphic cutaneous manifestations and nonspecific histopathological findings. ( 29781265 )
2018
16
Lymphocyte-Variant Hypereosinophilic Syndrome With Eosinophilic Myocarditis Treated With Steroids and Pegylated Interferon Alfa-2a. ( 29406050 )
2018
17
A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. ( 29785315 )
2018
18
Crescentic splinter haemorrhages reflect stroke pathophysiology in hypereosinophilic syndrome. ( 28891232 )
2017
19
Hypereosinophilic Syndrome After Liver Transplantation: A Case Report and a Review of the Literature. ( 28263223 )
2017
20
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. ( 28378039 )
2017
21
Eosinophilic myocarditis and hypereosinophilic syndrome. ( 28652675 )
2017
22
Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids. ( 28757367 )
2017
23
Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay. ( 28577656 )
2017
24
Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. ( 28374041 )
2017
25
Repeated Prosthetic Mitral Valve Thrombosis in FlukeA Infection Induced Hypereosinophilic Syndrome. ( 28219563 )
2017
26
When a death apparently associated to sexual assault is instead a natural death due to idiopathic hypereosinophilic syndrome: The importance of gamma-hydroxybutyric acid analysis in vitreous humor. ( 28527983 )
2017
27
Hypereosinophilic Syndrome With Eosinophilic Gastritis. ( 28491930 )
2017
28
Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure. ( 28347583 )
2017
29
Hypereosinophilic syndrome. ( 28052805 )
2017
30
The right atrium in idiopathic hypereosinophilic syndrome : Insights from the 3D speckle tracking echocardiographic MAGYAR-Path Study. ( 29234843 )
2017
31
Aortic stiffness is increased in patients with hypereosinophilic syndrome being in early necrotic phase. ( 29312868 )
2017
32
Hypereosinophilic syndrome with central nervous system involvement: Two case reports and literature review. ( 28945486 )
2017
33
A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. ( 28401108 )
2017
34
Hypereosinophilic syndrome: endomyocardial biopsy versus echocardiography to diagnose cardiac involvement. ( 28440714 )
2017
35
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. ( 28885361 )
2017
36
JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. ( 28111307 )
2017
37
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
38
Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. ( 28337408 )
2017
39
Multiple Valvular Complications of Hypereosinophilic Syndrome. ( 28290178 )
2016
40
Biventricular thrombus in hypereosinophilic syndrome presenting with shortness of breath. ( 27896330 )
2016
41
Lymphocytic variant of Hypereosinophilic syndrome with deep vein thrombosis. ( 27728750 )
2016
42
Characterization of left atrial dysfunction in hypereosinophilic syndrome - Insights from the Motion analysis of the heart and great vessels by three-dimensional speckle tracking echocardiography in pathological cases (MAGYAR-Path) Study. ( 27118091 )
2016
43
Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome. ( 27733964 )
2016
44
A Possible Case of Hepatitis due to Hypereosinophilic Syndrome. ( 27250051 )
2016
45
Superficial femoral artery thromosis secondary to hypereosinophilic syndrome. ( 27728032 )
2016
46
Generalized Recalcitrant Pruritus as the Presenting Manifestation of Hypereosinophilic Syndrome. ( 26826106 )
2016
47
Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- Extended follow-up. ( 27267517 )
2016
48
Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. ( 27231866 )
2016
49
Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. ( 27583887 )
2016
50
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. ( 27681117 )
2016
Sources

Variations for Hypereosinophilic Syndrome

About this section
Sources

Expression for Hypereosinophilic Syndrome

About this section
Search GEO for disease gene expression data for Hypereosinophilic Syndrome.
Sources

Pathways for Hypereosinophilic Syndrome

About this section

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.93 ABL1 CCL11 CSF2 EPX FGFR1 IFNA1
2
ERK Signaling 64
Show member pathways
 13.88 ABL1 CCL11 CCL17 CSF2 FGFR1 IL13
3
PEDF Induced Signaling 64
Show member pathways
 13.69 CCL11 CCL17 CSF2 FGFR1 IFNA1 IL13
4
Developmental Biology 66
Show member pathways
 13.52 ABL1 CSF2 FGFR1 IL2RA IL3 IL5
5
TGF-Beta Pathway 64
Show member pathways
 13.49 CCL11 CCL17 FGFR1 IFNA1 IL13 IL2RA
6
Akt Signaling 64
Show member pathways
 13.38 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
7
PAK Pathway 64
Show member pathways
 13.21 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
8
Cytokine Signaling in Immune system 66
Show member pathways
 13.18 CCL11 CSF2 FGFR1 IFNA1 IGHE IL13
9
Phospholipase-C Pathway 64
Show member pathways
 13.09 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
10
p70S6K Signaling 64
Show member pathways
 13.07 FGFR1 IL2RA IL3 IL4 KIT PDGFRA
11
PI3K-Akt signaling pathway 37
Show member pathways
 13.03 FGFR1 IFNA1 IL2RA IL3 IL4 KIT
12
Endometrial cancer 37
Show member pathways
 12.91 ABL1 CSF2 FGFR1 IL3 KIT PDGFRA
13
Ras signaling pathway 37
Show member pathways
 12.73 ABL1 FGFR1 KIT PDGFRA PDGFRB
14
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.64 CSF2 IGHE IL13 IL3 IL4 IL5
15
NF-kappaB Signaling 4
12.58 IFNA1 IL2RA IL3 IL4 KIT
16
Apoptosis Pathway 72
Show member pathways
 12.5 FGFR1 IL13 IL2RA IL5 PDGFRA PDGFRB
17
Th17 cell differentiation 37
Show member pathways
 12.43 IL13 IL2RA IL4 IL5
18
Pathways in cancer 37
12.42 ABL1 FGFR1 IFNA1 IL13 IL2RA IL3
19
HTLV-I infection 37
12.41 CSF2 IL2RA PDGFRA PDGFRB
20
IL-17 Family Signaling Pathways 65
Show member pathways
 12.4 CCL11 CCL17 CSF2 IL13 IL4 IL5
21
Regulation of IFNA signaling 66
Show member pathways
 12.4 CSF2 IFNA1 IL13 IL2RA IL3 IL4
22
Tyrosine Kinases / Adaptors 4
12.18 ABL1 FGFR1 KIT PDGFRA PDGFRB
23
G beta-gamma signalling through PI3Kgamma 66
Show member pathways
 12.16 CSF2 IL2RA IL3 IL5
24
AKT Signaling Pathway 67
12.15 FGFR1 IL2RA PDGFRA PDGFRB
25
Allograft rejection 1 37
Show member pathways
 12.14 ABL1 CCL11 EPX IFNA1 IL13 IL2RA
26
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.13 CCL11 CCL17 FGFR1 IL13 IL2RA IL3
27
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.07 CSF2 IL2RA IL3 IL4 IL5 KIT
28
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.06 FGFR1 PDGFRA PDGFRB
29
Interleukin-4 and 13 signaling 66
12.02 CCL11 IGHE IL13 IL4
30
Hematopoietic cell lineage 37
11.96 CSF2 IL2RA IL3 IL4 IL5 KIT
31
Jak-Stat Signaling Pathway 67
11.92 ABL1 IFNA1 IL2RA IL3
32
Innate Lymphoid Cell Differentiation Pathways 65
11.88 IL13 IL2RA IL4 IL5 KIT
33
Glucocorticoid receptor regulatory network 1
11.85 CSF2 IL13 IL4 IL5
34
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.85 CSF2 IL2RA IL3 IL4 IL5
35
Angiogenesis (CST) 4
11.83 FGFR1 PDGFRA PDGFRB
36
VEGF Pathway (Tocris) 72
Show member pathways
 11.79 FGFR1 KIT PDGFRB
37
IL4-mediated signaling events 1
11.76 CCL11 CCL17 IGHE IL4 IL5
38
Central carbon metabolism in cancer 37
11.75 FGFR1 KIT PDGFRA PDGFRB
39
Lung fibrosis 1
11.74 CCL11 CSF2 IL13 IL4 IL5
40
Gefitinib Pathway, Pharmacokinetics 61
Show member pathways
 11.72 ABL1 KIT PDGFRA PDGFRB
41
Interleukin-10 signaling 66
11.55 CSF2 IL13 IL4
42
Hematopoietic Stem Cell Differentiation 1
11.54 CSF2 IL3 IL5
43
Alzheimers Disease Pathway 64
11.51 FGFR1 PDGFRA PDGFRB
44
Vemurafenib Pathway, Pharmacodynamics 61
11.47 FGFR1 PDGFRA PDGFRB
45
Th2 Differentiation Pathway 65
11.46 CCL11 CCL17 IL13 IL2RA IL4 IL5
46
Inflammatory Response Pathway 1
11.36 IL2RA IL4 IL5
47
Development and heterogeneity of the ILC family 1
11.34 IL13 IL4 IL5
48
Cytokines and Inflammatory Response 1
11.31 CSF2 IL13 IL3 IL4 IL5
49
OX40 Pathway 64
11.23 IL13 IL4 IL5
50
Osteoblast Signaling 1
10.85 PDGFRA PDGFRB
Sources

GO Terms for Hypereosinophilic Syndrome

About this section

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CCL17 CSF2 EPX IFNA1 IL13
2 receptor complex GO:0043235 9.56 FGFR1 KIT PDGFRA PDGFRB
3 external side of plasma membrane GO:0009897 9.55 IGHE IL13 IL2RA KIT PDGFRA
4 extracellular region GO:0005576 9.44 CCL11 CCL17 CSF2 EPX FGFR1 IFNA1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 ABL1 CSF2 FGFR1 KIT
2 defense response to bacterium GO:0042742 9.98 EPX IGHE PRG2 RNASE3
3 positive regulation of cell proliferation GO:0008284 9.98 CSF2 FGFR1 IL3 IL5 KIT PDGFRA
4 positive regulation of cell migration GO:0030335 9.97 CCL11 KIT PDGFRA PDGFRB
5 chemotaxis GO:0006935 9.96 CCL11 CCL17 PDGFRA PDGFRB
6 positive regulation of protein kinase B signaling GO:0051897 9.95 FGFR1 KIT PDGFRA PDGFRB
7 positive regulation of MAPK cascade GO:0043410 9.94 FGFR1 KIT PDGFRA PDGFRB
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.91 ABL1 KIT PDGFRA PDGFRB
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 ABL1 CCL11 CCL17 FGFR1 KIT PDGFRA
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 ABL1 IL3 IL5
11 negative regulation of signal transduction GO:0009968 9.86 FGFR1 KIT PDGFRA PDGFRB
12 MAPK cascade GO:0000165 9.86 CSF2 FGFR1 IL2RA IL3 IL5 KIT
13 cell chemotaxis GO:0060326 9.85 KIT PDGFRA PDGFRB
14 protein autophosphorylation GO:0046777 9.85 ABL1 FGFR1 KIT PDGFRA PDGFRB
15 immune response GO:0006955 9.85 CCL11 CCL17 CSF2 IGHE IL13 IL2RA
16 phosphatidylinositol phosphorylation GO:0046854 9.84 FGFR1 KIT PDGFRA PDGFRB
17 positive regulation of MAP kinase activity GO:0043406 9.83 FGFR1 KIT PDGFRB
18 phosphatidylinositol-mediated signaling GO:0048015 9.81 FGFR1 PDGFRA PDGFRB
19 positive regulation of kinase activity GO:0033674 9.81 FGFR1 KIT PDGFRA PDGFRB
20 positive regulation of B cell proliferation GO:0030890 9.8 IL13 IL4 IL5
21 positive regulation of DNA replication GO:0045740 9.8 CSF2 IL3 PDGFRA
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 FGFR1 KIT PDGFRA PDGFRB
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.78 ABL1 IL13 IL4
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 CSF2 IL13 IL3 KIT
25 platelet-derived growth factor receptor signaling pathway GO:0048008 9.74 ABL1 PDGFRA PDGFRB
26 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.72 KIT PDGFRA PDGFRB
27 embryonic hemopoiesis GO:0035162 9.7 IL3 KIT
28 negative regulation of interleukin-10 production GO:0032693 9.69 EPX PRG2
29 dendritic cell differentiation GO:0097028 9.68 CSF2 IL4
30 positive regulation of podosome assembly GO:0071803 9.68 CSF2 IL5
31 response to fluid shear stress GO:0034405 9.67 CSF2 PDGFRB
32 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.67 PDGFRA PDGFRB
33 retina vasculature development in camera-type eye GO:0061298 9.66 PDGFRA PDGFRB
34 mast cell chemotaxis GO:0002551 9.65 CCL11 KIT
35 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.62 ABL1 PDGFRB
36 positive regulation of phospholipase C activity GO:0010863 9.62 FGFR1 KIT PDGFRA PDGFRB
37 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.6 PDGFRA PDGFRB
38 defense response to nematode GO:0002215 9.59 EPX PRG2
39 metanephric glomerular capillary formation GO:0072277 9.58 PDGFRA PDGFRB
40 negative regulation of complement-dependent cytotoxicity GO:1903660 9.58 IL13 IL4
41 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
42 cytokine-mediated signaling pathway GO:0019221 9.32 CCL11 CSF2 IFNA1 IGHE IL13 IL2RA
43 protein phosphorylation GO:0006468 10.12 ABL1 CCL11 FGFR1 KIT PDGFRA PDGFRB
44 negative regulation of apoptotic process GO:0043066 10.09 FGFR1 IL4 KIT PDGFRA PDGFRB
45 regulation of signaling receptor activity GO:0010469 10.01 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
46 inflammatory response GO:0006954 10 CCL11 CCL17 IL13 IL2RA IL5 KIT

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.92 ABL1 FGFR1 KIT PDGFRA PDGFRB
2 growth factor activity GO:0008083 9.8 CSF2 IL3 IL4 IL5
3 cytokine activity GO:0005125 9.76 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
4 MAP kinase kinase kinase activity GO:0004709 9.71 FGFR1 KIT PDGFRA PDGFRB
5 mitogen-activated protein kinase kinase binding GO:0031434 9.67 FGFR1 KIT PDGFRA PDGFRB
6 growth factor binding GO:0019838 9.63 KIT PDGFRA PDGFRB
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 FGFR1 KIT PDGFRA PDGFRB
8 cytokine receptor binding GO:0005126 9.61 IFNA1 IL13 IL4
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
10 protein tyrosine kinase activity GO:0004713 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
11 platelet-derived growth factor receptor binding GO:0005161 9.54 PDGFRA PDGFRB
12 platelet-derived growth factor binding GO:0048407 9.51 PDGFRA PDGFRB
13 vascular endothelial growth factor binding GO:0038085 9.48 PDGFRA PDGFRB
14 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 FGFR1 IL2RA IL3 IL5 KIT
Sources

Sources for Hypereosinophilic Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....